Lexeo Therapeutics, Inc. (LXEO)

Over the past six months, Lexeo Therapeutics' stock has increased by 54.83%, reaching a 52-week high of $10.99 and a low of $1.45. In October 2025, the company received positive feedback from the FDA, potentially enabling a faster path to Accelerated Approval for LX2006. In November 2025, several analysts maintained or initiated coverage with positive ratings. In December 2025, Raymond James initiated coverage with a Strong Buy recommendation. In January 2026, the stock dropped 23% due to investor reaction to new clinical data for LX2020, and Lexeo Therapeutics announced key leadership appointments.

Information regarding demand seasonality for Lexeo Therapeutics' products and services was not found. The demand for its pipeline products is primarily driven by clinical trial progress, regulatory milestones, and the prevalence of the specific genetically defined diseases it aims to treat, rather than typical seasonal consumer patterns.

Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company focused on developing therapies for genetically defined cardiovascular diseases and a subgroup of Alzheimer's disease. The company operates within the Health Technology sector, specifically in the Biotechnology and Drug Discovery industries, and aims to translate scientific research into treatments for rare and prevalent cardiovascular conditions. Its product pipeline includes gene therapy candidates such as LX2006 for Friedreich's ataxia cardiomyopathy, LX1001 for APOE4 homozygous patients with Alzheimer's disease, LX2020 for PKP2-associated arrhythmogenic cardiomyopathy, LX2021 for inherited cardiac muscle disorders, and LX2022 for hypertrophic cardiomyopathy.

Lexeo Therapeutics, Inc. is headquartered in New York, NY, and focuses on addressing hereditary and acquired diseases with high unmet needs primarily in the United States.

Lexeo Therapeutics generally holds a positive brand reputation among analysts, with a consensus rating of "Moderate Buy". MarketBeat's evaluation indicates that Lexeo Therapeutics scored higher than 65% of companies in the medical sector. However, the company's reputation was impacted by a 23% stock drop in January 2026 after investors reacted negatively to new clinical data for LX2020, leading to at least one analyst lowering their price target.

Approximately 43.58% of Lexeo Therapeutics' stock is owned by Institutional Investors, 0.86% by Insiders, and 55.56% by Public Companies and Individual Investors. Major institutional owners include Janus Henderson Group Plc, Frazier Life Sciences Management, L.P., Balyasny Asset Management Llc, Vanguard Group Inc, Affinity Asset Advisors, LLC, Citadel Advisors Llc, Vestal Point Capital, LP, Woodline Partners LP, Millennium Management Llc, BlackRock, Inc., and RA Capital Management, L.P.